Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath, United Kingdom.
PLoS One. 2011 Feb 28;6(2):e17354. doi: 10.1371/journal.pone.0017354.
The progression of many human neurodegenerative disorders is associated with an accumulation of alpha-synuclein. Alpha-synuclein belongs to the homologous synuclein family, which includes beta-synuclein. It has been proposed that beta-synuclein may be a natural regulator of alpha-synuclein. Therefore controlling beta-synuclein expression may control the accumulation of alpha-synuclein and ultimately prevent disease progression. The regulation of synucleins is poorly understood. We investigated the transcriptional regulation of beta-synuclein, with the aim of identifying molecules that differentially control beta-synuclein expression levels. To investigate transcriptional regulation of beta-synuclein, we used reporter gene assays and bioinformatics. We identified a region -1.1/-0.6 kb upstream of the beta-synuclein translational start site to be a key regulatory region of beta-synuclein 5'-promoter activity in human dopaminergic cells (SH-SY5Y). Within this key promoter region we identified a metal response element pertaining to a putative Metal Transcription Factor-1 (MTF-1) binding site. We demonstrated that MTF-1 binds to this 5'-promoter region using EMSA analysis. Moreover, we showed that MTF-1 differentially regulates beta-synuclein promoter binding site, as well as beta-synuclein mRNA and protein expression. This effect of MTF-1 on expression was found to be specific to beta-synuclein when compared to alpha-synuclein. Understanding the regulation of synucleins and how they interact may point to molecular targets that could be manipulated for therapeutic benefit. In this study we showed that MTF-1 differentially controls the expression of beta-synuclein when compared to its homolog alpha-synuclein. This could potentially provide a novel targets or pathways for therapeutic intervention and/or treatment of synucleinopathies.
许多人类神经退行性疾病的进展都与α-突触核蛋白的积累有关。α-突触核蛋白属于同源突触核蛋白家族,该家族还包括β-突触核蛋白。有人提出,β-突触核蛋白可能是α-突触核蛋白的天然调节剂。因此,控制β-突触核蛋白的表达可能会控制α-突触核蛋白的积累,并最终防止疾病的进展。突触核蛋白的调节机制尚未完全阐明。我们研究了β-突触核蛋白的转录调控,旨在确定可差异化控制β-突触核蛋白表达水平的分子。为了研究β-突触核蛋白的转录调控,我们使用了报告基因检测和生物信息学方法。我们确定了β-突触核蛋白翻译起始位点上游的-1.1/-0.6kb 区域是人类多巴胺能细胞(SH-SY5Y)中β-突触核蛋白 5'-启动子活性的关键调控区。在这个关键启动子区域内,我们确定了一个金属反应元件,涉及到一个假定的金属转录因子-1(MTF-1)结合位点。我们通过 EMSA 分析证明了 MTF-1 与这个 5'-启动子区域结合。此外,我们还表明,MTF-1 可差异化调节β-突触核蛋白启动子结合位点以及β-突触核蛋白的 mRNA 和蛋白表达。与α-突触核蛋白相比,MTF-1 对表达的这种影响仅针对β-突触核蛋白。了解突触核蛋白的调节以及它们之间的相互作用可能指向可用于治疗获益的分子靶标。在这项研究中,我们表明 MTF-1 可差异化控制β-突触核蛋白的表达,与同源蛋白α-突触核蛋白相比。这可能为突触核蛋白病的治疗干预和/或治疗提供新的靶点或途径。